Andreas von Sprecher

Author

Also Known As

A von Sprecher, A. VON SPRECHER, A. Von Sprecher, A. von Sprecher, Andreas Von Sprecher, Andreas von Sprecher, Von Sprecher, A.

Publications

253

Citations

H-Index

Concepts

All Affiliations

Novartis (Switzerland)The University of Melbourne

About

Andreas von Sprecher is an author at Novartis (Switzerland) specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	177
2	Natural Sciences	3	3	67
3	Biochemistry	3	3	77
4	Engineering	1	1	63
5	Biomolecular Engineering	1	1	63

Andreas von Sprecher

Publications

240

Citations

H-Index

Page 1

	Year	Citations
The synthesis of pyridine derivatives from 3‐formylchromone Georges Haas, James L. Stanton, Andreas von Sprecher, Journal of Heterocyclic Chemistry Pyridine DerivativesDerivative (Chemistry)DerivativesEngineeringAbstract 3‐Formylchromone	1981	63
Novel cell-penetrating α-keto-amide calpain inhibitors as potential treatment for muscular dystrophy Cyrille Lescop, Holger Herzner, H. Siendt, Bioorganic & Medicinal Chemistry Letters Molecular PharmacologyBiochemistryMedicinePharmacologyDrug Discovery	2005	37
Synthesis and SAR of a novel, potent and structurally simple LTD4 antagonist of the quinoline class Andreas von Sprecher, Marc Gerspacher, A. Beck, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryNatural SciencesMedicineOrganic ChemistryChemistry	1998	27
Peptidoleukotriene antagonists: Structural analogs of leukotriene D4 with special emphasis on CGP 45715A Andreas von Sprecher, A. Beck, A. Sallmann, Drugs of the Future Anti-inflammatoryBiochemistryFunctional SelectivityNatural SciencesMedicine	1991	22
Dual neurokinin NK1/NK2 receptor antagonists Marc Gerspacher, Andreas von Sprecher Drugs of the Future Functional SelectivityMedicinePharmacologyImmunologyNeuropeptide Receptor	1999	19
Dual neurokinin NK1/NK2 antagonists: N-[(R,R)-(E)-1-arylmethyl-3-(2-oxo-azepan-3-yl)carbamoyl]allyl-N-methyl-3,5-bis(trifluoromethyl)benzamides and 3-[N′-3,5-bis(trifluoromethyl)benzoyl-N-arylmethyl-N′-methylhydrazino]-N-[(R)-2-oxo-azepan-3-yl]propionamides Marc Gerspacher, Luigi La Vecchia, Robert Mah, Bioorganic & Medicinal Chemistry Letters Molecular PharmacologyMedicinal ChemistryMedicinePharmacological AgentNeuropharmacology	2001	18
Peptidoleukotriene Antagonists State of the Art Andreas von Sprecher, Andreas Beck, Marc Gerspacher, CHIMIA International Journal for Chemistry AsthmaVitro PotencyMedicinal ChemistryPeptidoleukotriene Antagonists StateBiochemistry	1992	18
Neurokinin antagonists as potential therapies for inflammation and rheumatoid arthritis. Andreas von Sprecher, Marc Gerspacher, Gary P. Anderson PubMed InflammationRheumatologyRheumatoid DisorderAnti-inflammatoryAutoimmune Disease	1998	14
N-[(R,R)-(E)-1-(4-chloro-benzyl)-3-(2-oxo-azepan-3-ylcarbamoyl)-allyl]-N-methyl-3,5-bis-trifluoromethyl-benzamide: an orally active neurokinin NK1/NK2 antagonist Marc Gerspacher, Andreas von Sprecher, Robert Mah, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryMedicineMechanism Of ActionPharmacological AgentNeuropharmacology	2000	12
Biphenyl derivatives as novel dual NK1/NK2-receptor antagonists Robert Mah, Marc Gerspacher, Andreas von Sprecher, Bioorganic & Medicinal Chemistry Letters Functional SelectivityMedicineImmunologyPharmacological AgentPharmacotherapy	2002	10

Page 1